Procter & Gamble Reaffirms Fiscal 2026 Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy PG?
Source: NASDAQ.COM
- Earnings Guidance Confirmation: Procter & Gamble expects fiscal 2026 net earnings per share to rise by 1% to 6% from last year's $6.51, demonstrating confidence in its future profitability despite market challenges.
- Core Earnings Outlook: The company anticipates core earnings per share to range between $6.83 and $7.09, even with a projected $0.25 headwind from costs, indicating resilience in maintaining growth potential under adverse conditions.
- Sales Growth Guidance: P&G reaffirms its annual sales growth guidance of 1% to 5%, with foreign exchange rates, acquisitions, and divestitures expected to contribute approximately one percentage point to overall sales growth, showcasing its adaptability in the market.
- Positive Market Reaction: The stock rose by 3.07% to $150.20 in pre-market trading on the New York Stock Exchange, reflecting investor optimism regarding the company's outlook and performance prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PG
Wall Street analysts forecast PG stock price to rise
17 Analyst Rating
10 Buy
7 Hold
0 Sell
Moderate Buy
Current: 142.850
Low
150.00
Averages
164.50
High
180.00
Current: 142.850
Low
150.00
Averages
164.50
High
180.00
About PG
The Procter & Gamble Company is focused on providing branded consumer packaged goods to consumers across the world. The Company’s segments include Beauty, Grooming, Health Care, Fabric & Home Care and Baby, Feminine & Family Care. The Company’s products are sold in approximately 180 countries and territories primarily through mass merchandisers, e-commerce, including social commerce channels, grocery stores, membership club stores, drug stores, department stores, distributors, wholesalers, specialty beauty stores, including airport duty-free stores), high-frequency stores, pharmacies, electronics stores and professional channels. It also sells direct to individual consumers. It has operations in approximately 70 countries. It offers products under brands, such as Head & Shoulders, Herbal Essences, Pantene, Rejoice, Olay, Old Spice, Safeguard, Secret, SK-II, Braun, Gillette, Venus, Crest, Oral-B, Ariel, Downy, Gain, Tide, Always, Always Discreet, Tampax, Bounty and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Procter & Gamble Quarterly Earnings Exceed Expectations
- Earnings Beat: Procter & Gamble reported an adjusted earnings per share of $1.63, surpassing Wall Street's expectation of $1.56, indicating strong profitability driven by robust demand for beauty products.
- Significant Revenue Growth: The company's quarterly revenue reached $21.24 billion, exceeding the expected $20.5 billion by 6.3%, demonstrating P&G's strong sales performance in the market and reinforcing its competitive position.
- Net Income Increase: P&G's third-quarter net income was $3.93 billion, up 4% from $3.78 billion a year earlier, reflecting effective management in cost control and product demand.
- Stable Full-Year Outlook: The company reiterated its full-year earnings and sales forecasts, showcasing confidence in future market performance, which may attract more investor interest in its stock.
See More
Stock Index Futures Rise as Israel-Lebanon Ceasefire Extended
- FDA Rejection: AbbVie's anti-wrinkle therapy TrenibotE was not approved by the FDA, resulting in a 0.40% drop in its stock price, highlighting regulatory challenges that may impact future revenue growth in the biopharmaceutical sector.
- Strong Earnings Boost: Procter & Gamble's FQ3 earnings report revealed a 3% organic sales increase, surpassing the 2.8% market expectation, leading to a 3.4% rise in stock price, indicating broad-based growth across product categories and regions that enhances market confidence.
- Weight Loss Script Decline: Eli Lilly's weight loss drug Zepbound saw a ~2% drop in weekly prescriptions, while competitor Novo Nordisk's Wegovy prescriptions rose by 7%, causing Eli Lilly's stock to fall by 1.84%, reflecting the intense competition in the obesity treatment market.
- Microsoft's Buyout Offer: Microsoft offered voluntary buyouts to about 7% of its U.S. workforce, resulting in a 1.11% stock price increase, marking a strategic shift in response to the rise of artificial intelligence, which may affect its future human resource allocation.
See More
Consumer Stocks Show Mixed Performance Pre-Bell
- Market Performance: Consumer stocks exhibited mixed performance ahead of Friday's opening bell, reflecting divergent views on the economic outlook that could impact investor confidence and subsequent trading strategies.
- Sector Dynamics: Despite overall market fluctuations, certain stocks within the consumer goods sector may still be influenced by specific earnings reports or economic data, leading to standout or underperforming individual stocks.
- Investor Sentiment: Investors are showing caution while awaiting upcoming economic data, which may affect trading activity and market liquidity in the short term.
- Strategy Adjustments: Market participants might adjust their portfolios based on the performance of consumer stocks, particularly in the context of increasing economic uncertainty, seeking more robust investment options.
See More
Procter & Gamble Management Claims Worst Is Over
- Earnings Beat Expectations: Procter & Gamble reported a non-GAAP EPS of $1.59, exceeding expectations by $0.03, indicating resilience in the current economic climate, which may boost investor confidence and drive stock price appreciation.
- Strong Revenue Growth: The company achieved $21.24 billion in revenue for Q3, surpassing market expectations by $720 million, demonstrating P&G's solid sales performance amidst competitive pressures, which helps to solidify its market position.
- Management's Optimistic Outlook: P&G's management claims that the worst is over, and despite growth concerns, this positive signal could attract more investor attention and enhance market expectations for future performance.
- Future Growth Challenges: Despite strong financial results, concerns about P&G's future growth persist, necessitating effective strategies from management to address potential market volatility and competitive pressures.
See More
Procter & Gamble Reports Strong Q3 Earnings with Broad-Based Growth
- Strong Sales Growth: Procter & Gamble's organic sales rose 3% in Q3, surpassing the market expectation of 2.8%, indicating robust performance across product categories and regions, which further solidifies its market position.
- Beauty and Personal Care Outperformance: The beauty segment saw a 7% year-over-year organic sales increase, while personal care achieved high single-digit growth, primarily driven by innovation-based pricing and volume increases in North America and Europe, reflecting the company's innovative capabilities in a highly competitive market.
- Stable Health Care Segment: Health care organic sales grew 2%, with oral care sales impacted by volume declines in Greater China; however, innovation-based pricing and a favorable premium product mix in North America still contributed to overall growth, demonstrating market adaptability.
- Slight Decline in Profitability: Core gross margin decreased by 100 basis points year-over-year, primarily due to unfavorable mix and rising costs, but productivity gains and price increases partially offset this impact, showcasing the company's efforts in cost control.
See More
Procter & Gamble Q3 Earnings Exceed Expectations
- Strong Earnings Report: Procter & Gamble's Q3 non-GAAP EPS of $1.59 exceeded expectations by $0.03, demonstrating the company's resilience and profitability in the current economic climate.
- Significant Revenue Growth: The company reported revenue of $21.24 billion for Q3, surpassing market expectations by $720 million, reflecting sustained consumer demand for household products and reinforcing P&G's market leadership.
- Management Confidence: Management stated that 'the worst is over,' indicating an optimistic outlook for future performance, which may attract more investor interest in the stock.
- Industry Impact: P&G's robust earnings not only boosted its own stock price but also lifted the shares of other household goods companies, showcasing its leadership role in the industry and the restoration of market confidence.
See More
Procter & Gamble Quarterly Earnings Exceed Expectations
- Earnings Beat: Procter & Gamble reported an adjusted earnings per share of $1.63, surpassing Wall Street's expectation of $1.56, indicating strong profitability driven by robust demand for beauty products.
- Significant Revenue Growth: The company's quarterly revenue reached $21.24 billion, exceeding the expected $20.5 billion by 6.3%, demonstrating P&G's strong sales performance in the market and reinforcing its competitive position.
- Net Income Increase: P&G's third-quarter net income was $3.93 billion, up 4% from $3.78 billion a year earlier, reflecting effective management in cost control and product demand.
- Stable Full-Year Outlook: The company reiterated its full-year earnings and sales forecasts, showcasing confidence in future market performance, which may attract more investor interest in its stock.
See More
Stock Index Futures Rise as Israel-Lebanon Ceasefire Extended
- FDA Rejection: AbbVie's anti-wrinkle therapy TrenibotE was not approved by the FDA, resulting in a 0.40% drop in its stock price, highlighting regulatory challenges that may impact future revenue growth in the biopharmaceutical sector.
- Strong Earnings Boost: Procter & Gamble's FQ3 earnings report revealed a 3% organic sales increase, surpassing the 2.8% market expectation, leading to a 3.4% rise in stock price, indicating broad-based growth across product categories and regions that enhances market confidence.
- Weight Loss Script Decline: Eli Lilly's weight loss drug Zepbound saw a ~2% drop in weekly prescriptions, while competitor Novo Nordisk's Wegovy prescriptions rose by 7%, causing Eli Lilly's stock to fall by 1.84%, reflecting the intense competition in the obesity treatment market.
- Microsoft's Buyout Offer: Microsoft offered voluntary buyouts to about 7% of its U.S. workforce, resulting in a 1.11% stock price increase, marking a strategic shift in response to the rise of artificial intelligence, which may affect its future human resource allocation.
See More
Consumer Stocks Show Mixed Performance Pre-Bell
- Market Performance: Consumer stocks exhibited mixed performance ahead of Friday's opening bell, reflecting divergent views on the economic outlook that could impact investor confidence and subsequent trading strategies.
- Sector Dynamics: Despite overall market fluctuations, certain stocks within the consumer goods sector may still be influenced by specific earnings reports or economic data, leading to standout or underperforming individual stocks.
- Investor Sentiment: Investors are showing caution while awaiting upcoming economic data, which may affect trading activity and market liquidity in the short term.
- Strategy Adjustments: Market participants might adjust their portfolios based on the performance of consumer stocks, particularly in the context of increasing economic uncertainty, seeking more robust investment options.
See More
Procter & Gamble Management Claims Worst Is Over
- Earnings Beat Expectations: Procter & Gamble reported a non-GAAP EPS of $1.59, exceeding expectations by $0.03, indicating resilience in the current economic climate, which may boost investor confidence and drive stock price appreciation.
- Strong Revenue Growth: The company achieved $21.24 billion in revenue for Q3, surpassing market expectations by $720 million, demonstrating P&G's solid sales performance amidst competitive pressures, which helps to solidify its market position.
- Management's Optimistic Outlook: P&G's management claims that the worst is over, and despite growth concerns, this positive signal could attract more investor attention and enhance market expectations for future performance.
- Future Growth Challenges: Despite strong financial results, concerns about P&G's future growth persist, necessitating effective strategies from management to address potential market volatility and competitive pressures.
See More
Procter & Gamble Reports Strong Q3 Earnings with Broad-Based Growth
- Strong Sales Growth: Procter & Gamble's organic sales rose 3% in Q3, surpassing the market expectation of 2.8%, indicating robust performance across product categories and regions, which further solidifies its market position.
- Beauty and Personal Care Outperformance: The beauty segment saw a 7% year-over-year organic sales increase, while personal care achieved high single-digit growth, primarily driven by innovation-based pricing and volume increases in North America and Europe, reflecting the company's innovative capabilities in a highly competitive market.
- Stable Health Care Segment: Health care organic sales grew 2%, with oral care sales impacted by volume declines in Greater China; however, innovation-based pricing and a favorable premium product mix in North America still contributed to overall growth, demonstrating market adaptability.
- Slight Decline in Profitability: Core gross margin decreased by 100 basis points year-over-year, primarily due to unfavorable mix and rising costs, but productivity gains and price increases partially offset this impact, showcasing the company's efforts in cost control.
See More
Procter & Gamble Q3 Earnings Exceed Expectations
- Strong Earnings Report: Procter & Gamble's Q3 non-GAAP EPS of $1.59 exceeded expectations by $0.03, demonstrating the company's resilience and profitability in the current economic climate.
- Significant Revenue Growth: The company reported revenue of $21.24 billion for Q3, surpassing market expectations by $720 million, reflecting sustained consumer demand for household products and reinforcing P&G's market leadership.
- Management Confidence: Management stated that 'the worst is over,' indicating an optimistic outlook for future performance, which may attract more investor interest in the stock.
- Industry Impact: P&G's robust earnings not only boosted its own stock price but also lifted the shares of other household goods companies, showcasing its leadership role in the industry and the restoration of market confidence.
See More
